Dr. Campbell is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
MD Anderson Cancer Center, Department of GU Medical Oncology
1155 Pressler St, CPB 7.3450, Unit 1374
Houston, TX 77030Phone+1 713-792-2121Fax+1 713-745-0422
Education & Training
- University of Texas Graduate School of Biomedical SciencesMasters in Science, Biomedical Research and Translational Research, 2013 - 2015
- University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2012 - 2015
- Indiana University School of MedicineChief Residency, Internal Medicine, 2011 - 2012
- Indiana University School of MedicineResidency, Internal Medicine, 2008 - 2011
- Indiana University School of MedicineClass of 2007
Certifications & Licensure
- FL State Medical License 2021 - Present
- TN State Medical License 2024 - 2027
- GA State Medical License 2024 - 2026
- AZ State Medical License 2024 - 2025
- LA State Medical License 2024 - 2025
- MS State Medical License 2024 - 2025
- OK State Medical License 2020 - 2025
- Join now to see all
Awards, Honors, & Recognition
- Teacher of the Year Award MD Anderson Cancer Center Hematology/Medical Oncology Fellowship, 2018
- Humanitas Award for Excellent Patient Care UT MD Anderson Cancer Center, 2015
- Chief Fellow Hematology/Medical Oncology Fellowship MD Anderson Cancer Center, 2014-2015
- Join now to see all
Clinical Trials
- Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors Start of enrollment: 2017 Dec 28
- Daratumumab in Treating Patients With Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer Start of enrollment: 2018 May 29
- Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma Start of enrollment: 2018 May 15
- Join now to see all
Publications & Presentations
PubMed
- 29 citationsA phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy.Pavlos Msaouel, Sangeeta Goswami, Peter F Thall, Xuemei Wang, Ying Yuan
Science Translational Medicine. 2022-04-20 - 13 citationsPhase II trial of neoadjuvant sitravatinib plus nivolumab in patients undergoing nephrectomy for locally advanced clear cell renal cell carcinoma.Jose A Karam, Pavlos Msaouel, Cara L Haymaker, Surena F Matin, Matthew T Campbell
Nature Communications. 2023-05-10 - 92 citationsPhase 2 study of pembrolizumab in patients with advanced rare cancers.Aung Naing, Funda Meric-Bernstam, Bettzy Stephen, Daniel D. Karp, Joud Hajjar
Journal for Immunotherapy of Cancer. 2020-03-01
Journal Articles
- Author Correction: Fecal Microbiota Transplantation for Refractory Immune Checkpoint Inhibitor-Associated ColitisMatthew T Campbell, Jennifer A Wargo, John R Stroehlein, Padmanee Sharma, Sumit K Subudhi, Gottumukkala S Raju, Jianjun Gao, Alexander J Lazar, Dipen M Maru, Michael T..., Nature
- Fecal Microbiota Transplantation for Refractory Immune Checkpoint Inhibitor-Associated ColitisJohn R Stroehlein, Sumit K Subudhi, Jennifer A Wargo, Dipen M Maru, Gottumukkala S Raju, Jianjun Gao, Matthew T Campbell, Michael T Tetzlaff, Padmanee Sharma, Nature
- IL-18 Mediates Pro-apoptotic Signaling in Renal Tubular Cells through a Fas Ligand-dependent MechanismZhang, H. Hile, K., Asunuma, H., Vandedrbrink, B., Franke, E., Campbell, MT, Meldrum, KK, American Journal of Physiology- Renal Physiology, 7/1/2011
- Join now to see all
Abstracts/Posters
- Phase I trial of sunitinib and temsirolus in metastatic renal cell carcinoma.Campbell MT, Millikan R, Emre A, Xiao L, Tannir NM., GU ASCO, San Francisco, 2/2014
- Phase I Trial of Sunitinib (S) And Temsirolimus (T) In Metastatic Renal Cell Carcinoma (mRCC)Campbell, MT, Millikan, R., Emre, A.,Xiao, L., Tannir, NM, Genitourinary American Society of Clinical Oncology Meeting, San Francisco, CA, 2/1/2014
- Germline single nucleotide polymorphism (SNP) predictors of progression free survival and overall survival in advanced prostate cancer patients treated with androgen d...Campbell MT, Jung J, Phillips S, Mohammadi Y, Carr KA, Davis TL, Li L, Sweeney CJ, Skaar TC, Hahn N, Genitourinary ASCO, Orlando, FL, 2/2011
- Join now to see all
Press Mentions
- CAR T-cell Therapy for Kidney Cancer Builds on Efficacy RecordNovember 9th, 2024
- DFW Healthcare Brief: UTSW Coppell Is Now Open and Medical City Frisco’s AI-Driven Spine Surgery SystemApril 26th, 2023
- UTSW and Children’s Health to Lead Paediatric Cancer Combo Therapy TrialApril 25th, 2023
- Join now to see all
Grant Support
- Young Investigator AwardConquer Cancer Foundation/Kidney Cancer Association2015–2016
- National Institute of Health Loan Repayment AwardNational Institute of Health2014–2016
Professional Memberships
- Member
- Member
- Member
- American Urology AssociationMember
- Society of Urologic OncologyMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: